These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36166670)

  • 1. Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic.
    Ganetsky VS; Salzman M; Carroll G; Heil J; Sutton J; Visioli VM; Currie S; Schmidt R; Baston KE; Haroz R
    J Addict Med; 2023 Jan-Feb 01; 17(1):108-110. PubMed ID: 36166670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 7. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
    Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
    Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of long-acting injectable buprenorphine in the correctional setting.
    Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
    J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
    Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
    J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
    Lai M; Bowman J; Charles J; Smid MC
    J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release buprenorphine outcomes among treatment resistant veterans.
    Cotton AJ; Lo K; Kurtz FB; Waldbauer L
    Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
    [No Abstract]   [Full Text] [Related]  

  • 17. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report.
    Barrett J; Schapiro R; Casey E; Chertok J
    J Addict Med; 2024 Mar-Apr 01; 18(2):209-211. PubMed ID: 38227854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
    Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
    Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
    J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.